Related content

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

By Konecny G.  

Breast Cancer Research and Treatment, Vol. 69, Iss. 1, 2001-09 ,pp. : 53-63

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite

Pathologic Changes Related to CMF Primary Chemotherapy in Breast Cancer

By Moreno A.   Escobedo A.   Benito E.   Serra J.M.   Gumà A.   Riu F.  

Breast Cancer Research and Treatment, Vol. 75, Iss. 2, 2002-09 ,pp. : 119-125

Springer Publishing Company

Access to resources Recommend Favorite